4head Cutaneous Stick: Clinical Particulars
Active ingredient: levomenthol
- 1. Name of the medicinal product
- 2. Qualitative and quantitative composition
- 3. Pharmaceutical form
- 4. Clinical particulars
- 4.1 Therapeutic indications
- 4.2 Posology and method of administration
- 4.3 Contraindications
- 4.4 Special warnings and precautions for use
- 4.5 Interaction with other medicinal products and other forms of interaction
- 4.6 Pregnancy and lactation
- 4.7 Effects on ability to drive and use machines
- 4.8 Undesirable effects
- 4.9 Overdose
- 5. Pharmacological properties
- 5.1 Pharmacodynamic properties
- 5.2 Pharmacokinetic properties
- 5.3 Preclinical safety data
- 6. Pharmaceutical particulars
- 6.1 List of excipients
- 6.2 Incompatibilities
- 6.3 Shelf life
- 6.4 Special precautions for storage
- 6.5 Nature and contents of container
- 6.6 Special precautions for disposal and other handling
- 7. Marketing authorisation holder
- 8. Marketing authorisation number(s)
- 9. Date of first authorisation/renewal of the authorisation
- 10. Date of revision of the text
1. Name of the medicinal product
4HEAD™ CUTANEOUS STICK
2. Qualitative and quantitative composition
Levomenthol 90% w/w.
For full list of excipients, see section List of excipients.
3. Pharmaceutical form
Cutaneous Stick.
4. Clinical particulars
4.1 Therapeutic indications
For the relief of headaches.
4.2 Posology and method of administration
4head is to be applied gently to the forehead. To be used as required, but excessive use avoided. If symptoms persist or worsen seek medical advice. For external topical application only.
4.3 Contraindications
Not recommended in patients where there is a known hypersensitivity to menthol.
4.4 Special warnings and precautions for use
Keep away from the eyes, levomenthol is irritant if allowed to come into contact with the eyes.
For single patient use only. For topical use - not to be taken.
4.5 Interaction with other medicinal products and other forms of interaction
None known.
4.6 Pregnancy and lactation
There is no information on safety when used during pregnancies and breast feeding, but there should be no hazard when applied as advised.
4.7 Effects on ability to drive and use machines
None known.
4.8 Undesirable effects
Menthol may give rise to hypersensitivity reactions including contact dermatitis. Because levomenthol is volatile, in rare cases it may cause temporary, mild watering of the eyes.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
4.9 Overdose
If accidentally ingested menthol is reported to cause severe abdominal pain, nausea, vomiting, vertigo, ataxia, drowsiness and coma. Treatment for accidental ingestion is by emptying the stomach by gastric lavage. A saline laxative and activated charcoal should be administered. Convulsions may be controlled by the slow intravenous administration of diazepam. Haemodialysis with a lipid dialysate has been employed.
5. Pharmacological properties
5.1 Pharmacodynamic properties
Applied to the skin, menthol dilates local blood vessels, causing a sensation of coldness, followed by an analgesic effect.
5.2 Pharmacokinetic properties
After absorption, menthol is excreted in the urine and bile as the glucuronide.
5.3 Preclinical safety data
No special information.
6. Pharmaceutical particulars
6.1 List of excipients
Macrogol 20000; Peppermint Oil.
6.2 Incompatibilities
None known.
6.3 Shelf life
36 months.
6.4 Special precautions for storage
Do not store above 25°C.
To be kept away from heat. (Melts at about 49-56°C).
6.5 Nature and contents of container
Plastic twist-up dispenser containing 3.6 g menthol, with plastic cover.
6.6 Special precautions for disposal and other handling
To be applied as directed. For single patient use only.
7. Marketing authorisation holder
Diomed Developments Limited
Tatmore Place, Gosmore
Hitchin, Herts SG4 7QR, UK
8. Marketing authorisation number
00173/0193.
9. Date of first authorisation/renewal of the authorisation
12 January 2009.
10. Date of revision of the text
May 2018.
